Log in

Relevant bibliographies by topics / Coronary heart disease – Chemotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Coronary heart disease – Chemotherapy.

Journal articles on the topic 'Coronary heart disease – Chemotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Coronary heart disease – Chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Palmer, S. C., J. Carver, L. Jacobs, et al. "Assessment of coronary heart disease risk in testicular cancer survivors." Journal of Clinical Oncology 24, no. 18_suppl (2006): 4592. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4592.

Full text

Abstract:

4592 Background: Testicular cancer survivors (TCS) who receive cisplatin-based chemotherapy (CBCT) are reported to have an increased risk of coronary heart disease (CHD) compared to chemo-naive TCS (J Clin Oncol 21:1513–1523, 2003). We hypothesized that TCS treated with CBCT would demonstrate abnormal objective measures of future CHD risk compared to chemo-naive TCS. Methods: TCS ≥ 2 years from diagnosis underwent evaluation using established objective measures predictive of future CHD risk: body mass index (BMI), Framingham relative risk (RR), flow-mediated endothelium-dependent vasodilation

APA, Harvard, Vancouver, ISO, and other styles

2

Сергеева, N. Sergeeva, Коломиец, et al. "Evaluation of Spent Pharmacotherapy in the Patients with Coronary Heart Disease Associated with Pulmonary Tuberculosis by means of the Neural Network." Journal of New Medical Technologies 21, no. 4 (2014): 108–12. http://dx.doi.org/10.12737/7281.

Full text

Abstract:

Current, the programs of mass prevention of the cardiovascular diseases, based on preventive medicinal correction of risk factors of cardiovascular diseases, such as hyperlipidemia, arterial hypertension, diabetes mellitus, are developed and realized. Pulmonary tuberculosis influences on state of blood system, which can be considered as functional disorders of the cardiovascular system caused by tuberculosis. These violations caused by concomitant tuberculosis lung diseases, such as cardiovascular and other diseases of the respiratory system. Specific (tuberculosis) damages of the heart

APA, Harvard, Vancouver, ISO, and other styles

3

Bachmeyer, Claude, Hervé Joly, and Roland Jorest. "Early Myocardial Infarction during Chemotherapy for Testicular Cancer." Tumori Journal 86, no. 5 (2000): 428–30. http://dx.doi.org/10.1177/030089160008600513.

Full text

Abstract:

A 36-year-old man with testicular cancer had an acute myocardial infarction during the first course of chemotherapy with bleomycin, etoposide and cisplatin. Since the patient had no significant risk factors for coronary heart disease, the infarction was likely to be attributable to the chemotherapy regimen. The physiopathological mechanisms of this causal relationship are discussed here.

APA, Harvard, Vancouver, ISO, and other styles

4

Ozben, Beste, Ramazan Kurt, Huseyin Oflaz, et al. "Acute Anterior Myocardial Infarction After Chemotherapy for Testicular Seminoma in a Young Patient." Clinical and Applied Thrombosis/Hemostasis 13, no. 4 (2007): 439–42. http://dx.doi.org/10.1177/1076029607303334.

Full text

Abstract:

Testicular cancer is the most common solid tumor among young men aged 15 to 35 years. Combination chemotherapy with cisplatin, etoposide, and bleomycin remains the mainstay of treatment. We present a 27-year-old man who presented with an acute anterior myocardial infarction during the second course of chemotherapy for seminoma. Because the patient had no significant risk factors for coronary heart disease, the infarction was likely caused by the chemotherapy regimen.

APA, Harvard, Vancouver, ISO, and other styles

5

Hader, Shelby N., Natalya Zinkevich, Laura E. Norwood Toro, et al. "Detrimental effects of chemotherapy on human coronary microvascular function." American Journal of Physiology-Heart and Circulatory Physiology 317, no. 4 (2019): H705—H710. http://dx.doi.org/10.1152/ajpheart.00370.2019.

Full text

Abstract:

Chemotherapy (CT) is a necessary treatment to prevent the growth and survival of cancer cells. However, CT has a well-established adverse impact on the cardiovascular (CV) system, even years after cessation of treatment. The effects of CT drugs on tumor vasculature have been the focus of much research, but little evidence exists showing the effects on the host microcirculation. Microvascular (MV) dysfunction is an early indicator of numerous CV disease phenotypes, including heart failure. The goal of this study was to evaluate the direct effect of doxorubicin (Dox) on human coronary MV functio

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Dingguo, Liansheng Wang, and Zhijian Yang. "Recurrent Syncope Associated with Lung Cancer." Case Reports in Medicine 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/309784.

Full text

Abstract:

Syncope is an important problem in clinical practice with many possible causes that might be misdiagnosed. We present an unusual case of syncope, which has a normal chest X-ray. Exercise EKG and coronary angioplasty results confirmed the existence of serious coronary heart disease. The patient was treated with coronary stent transplantation. However, scope occurred again and the elevated tumor makers cytokeratin-19-fragment and neuron-specific enolase revealed the bronchogenic carcinoma, which was confirmed by enhanced CT examination. The treatment of carcinoma by chemotherapy was indeed suffi

APA, Harvard, Vancouver, ISO, and other styles

7

Daher, Iyad N., Jose Banchs, Syed Wamique Yusuf, Elie Mouhayar, Jean-Bernard Durand, and Gregory Gladish. "Impact of Cardiac Computed Tomographic Angiography Findings on Planning of Cancer Therapy in Patients with Concomitant Structural Heart Disease." Cardiology Research and Practice 2011 (2011): 1–7. http://dx.doi.org/10.4061/2011/268058.

Full text

Abstract:

Background. Exclusion of underlying coronary artery disease (CAD) is essential in the diagnosis of chemotherapy-induced cardiomyopathy. Presence and severity of CAD can also impact the choice of therapy in cancer patients. The value of cardiac computed tomographic angiography (CCTA) in this setting has not been reported.Methods. We collected data on the clinical presentation and indications for CCTA performed from January to December 2008 at the University of Texas MD Anderson Cancer Center (MDACC). All examinations were performed using a 64-detector scanner. CCTA results and subsequent treatm

APA, Harvard, Vancouver, ISO, and other styles

8

van Leeuwen, Flora E., and Andrea K. Ng. "Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment." Hematology 2016, no. 1 (2016): 323–30. http://dx.doi.org/10.1182/asheducation-2016.1.323.

Full text

Abstract:

Abstract Long-term survivors of Hodgkin lymphoma (HL) experience several late adverse effects of treatment, with second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs) being the leading causes of death in these patients. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies (thyroid dysfunction, infertility), neck muscle atrophy, and persistent fatigue. HL survivors have two- to fourfold increased risks to develop SMNs and CVD compared with the general population. With respect to SMNs, radiotherapy is associated with 1.5- to 15-fold increas

APA, Harvard, Vancouver, ISO, and other styles

9

Chaulin, A. M., and D. V. Duplyakov. "Increased natriuretic peptides not associated with heart failure." Russian Journal of Cardiology 25 (January 11, 2021): 4140. http://dx.doi.org/10.15829/1560-4071-2020-4140.

Full text

Abstract:

Natriuretic peptides (NPs) are key diagnostic and prognostic biomarkers for patients with heart failure (HF). The main mechanism for increasing serum NP levels, which is characteristic of heart failure, is secretion in response to myocardial wall distention. At the same time, according to Russian and foreign literature, an increase in NPs is reported in a number of many other conditions that are not associated with HF. The study of these causes and mechanisms is necessary to improve the differential diagnosis of HF.This article discusses the mechanisms of increasing NPs and their diagnostic va

APA, Harvard, Vancouver, ISO, and other styles

10

Karev, E. A., S. L. Verbilo, E. G. Malev, et al. "Myocardial strain echocardiographic assessment: from theory to practice." Translational Medicine 7, no. 6 (2020): 16–28. http://dx.doi.org/10.18705/2311-4495-2020-7-6-16-28.

Full text

Abstract:

Assessment of systolic and diastolic ventricular function is one of the main goals of echocardiography. Nevertheless, some patients require data beyond standard echocardiographic protocol for making more precise clinical decision and prognosis determination. The spectrum of novel parameters, including myocardial strain and strain rate, provides more comprehensive evaluation of the initial changes in myocardium in a variety of clinical conditions. New methods of quantifying the systolic function of left and right ventricles can be applied in patients with arterial hypertension, coronary heart d

APA, Harvard, Vancouver, ISO, and other styles

11

Prasad, Megha, Michel T. Corban, Timothy D. Henry, Allan B. Dietz, Lilach O. Lerman, and Amir Lerman. "Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease." Cardiovascular Research 116, no. 8 (2020): 1424–33. http://dx.doi.org/10.1093/cvr/cvaa027.

Full text

Abstract:

Abstract CD34+ cells are haematopoietic stem cells used therapeutically in patients undergoing radiation or chemotherapy due to their regenerative potential and ability to restore the haematopoietic system. In animal models, CD34+ cells have been associated with therapeutic angiogenesis in response to ischaemia. Several trials have shown the potential safety and efficacy of CD34+ cell delivery in various cardiovascular diseases. Moreover, Phase III trials have now begun to explore the potential role of CD34+ cells in treatment of both myocardial and peripheral ischaemia. CD34+ cells have been

APA, Harvard, Vancouver, ISO, and other styles

12

Champeaux, Anne L., Jason L. Blaser, Jerome B. Myers, and David T. Schachter. "Multiple Myeloma Involving the Myocardium and Coronary Vessels." Archives of Pathology & Laboratory Medicine 124, no. 6 (2000): 910–12. http://dx.doi.org/10.5858/2000-124-0910-mmitma.

Full text

Abstract:

Abstract We report a case of metastatic plasmacytoma to the myocardium and coronary vessels in a 57-year-old man with multiple myeloma. Originally, the patient had a large plasmacytoma in his left chest wall and lung. He received local radiation and chemotherapy. Subsequently, the patient presented with symptoms of congestive heart failure. He had no prior history of cardiac disease. The patient was treated medically and later died from respiratory failure. At autopsy, a metastatic plamacytoma was indentified within the myocardium and externally compressing the coronary arteries. The tumor inf

APA, Harvard, Vancouver, ISO, and other styles

13

Gangaraju, Radhika, Yanjun Chen, Lindsey Hageman, et al. "Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors." Blood 136, Supplement 1 (2020): 17–18. http://dx.doi.org/10.1182/blood-2020-137731.

Full text

Abstract:

INTRODUCTION: Exposure to total body irradiation (TBI) increases the risk for cardiovascular risk factors (CVRFs) such as diabetes, hypertension and dyslipidemia in Blood or Marrow Transplant (BMT) survivors with the potential to increase the risk of post-BMT Coronary Heart Disease (CHD). Chest radiation is associated with accelerated atherosclerosis in conventionally treated patients. These factors, with or without additional factors such as smoking likely place BMT survivors at a high risk for CHD. Yet, a comprehensive evaluation of the risk of late-occurring CHD in BMT survivors is lacking.

APA, Harvard, Vancouver, ISO, and other styles

14

Picano, Eugenio, Quirino Ciampi, Lauro Cortigiani, et al. "Stress Echo 2030: The Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging." Journal of Clinical Medicine 10, no. 16 (2021): 3641. http://dx.doi.org/10.3390/jcm10163641.

Full text

Abstract:

With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tet

APA, Harvard, Vancouver, ISO, and other styles

15

Gros, Rosine, Vincent Hugon, Jean-Marc Thouret, and Vincent Peigne. "Coronary Spasm after an Injection of Vincristine." Chemotherapy 62, no. 3 (2017): 169–71. http://dx.doi.org/10.1159/000455224.

Full text

Abstract:

Cardiotoxicity, including heart failure, thromboembolic events, and myocardial ischemia, is a concern for cardiologists and oncologists. The most frequently involved drugs are anthracyclines. We report an episode of coronary spasm due to vincristine, a vinca alkaloid, in a 49-year-old man treated for a diffuse undifferentiated carcinoma. The patient suffered recurrent episodes of typical chest pain with ST-elevation in the inferior area. Coronary spasm was confirmed by an angiogram, which showed normal coronary arteries. No recurrence occurred with the medical management. Coronary spasm induce

APA, Harvard, Vancouver, ISO, and other styles

16

Alsara, Osama, Ahmad Alsarah, Jagadeesh K. Kalavakunta, Heather Laird-Fick, and George S. Abela. "Isolated Left Main Coronary Artery Stenosis after Thoracic Radiation Therapy: To Operate or Not to Operate." Case Reports in Medicine 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/834164.

Full text

Abstract:

Radiation therapy of neoplasms involving the chest or mediastinum results in a wide spectrum of cardiac complications including coronary artery disease, which can present in patients with few or no traditional cardiac risk factors. We report a case of radiation induced coronary artery disease in a 60-year-old female with a history of stage IIIA nonsmall cell lung carcinoma which was diagnosed eight years earlier and treated with chemotherapy and radiotherapy. She presented to the hospital with atypical chest pain that had occurred intermittently over the preceding week. Her initial electrocard

APA, Harvard, Vancouver, ISO, and other styles

17

Tew, Yong Yong, and Anne Scott. "Cardiac amyloidosis masquerading as acute coronary syndrome." BMJ Case Reports 14, no. 2 (2021): e238499. http://dx.doi.org/10.1136/bcr-2020-238499.

Full text

Abstract:

A 53-year-old man presented to a district general hospital with chest pain, ECG changes and a small high-sensitivity cardiac troponin I rise. There were no symptoms of heart failure. CT coronary angiography revealed moderate calcific disease and conventional angiography confirmed no flow limitation. Echocardiography showed left ventricular hypertrophy (LVH). His blood pressure remained normal throughout his admission. The tertiary centre labelled this as a ‘plaque rupture’ event but the LVH remained unexplained. Cardiac MRI displayed an unusual pattern of late gadolinium enhancement, which was

APA, Harvard, Vancouver, ISO, and other styles

18

Lindsey, Merry L., Richard A. Lange, Helen Parsons, Thomas Andrews, and Gregory J. Aune. "The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure." American Journal of Physiology-Heart and Circulatory Physiology 307, no. 10 (2014): H1379—H1389. http://dx.doi.org/10.1152/ajpheart.00099.2014.

Full text

Abstract:

Since the modern era of cancer chemotherapy that began in the mid-1940s, survival rates for children afflicted with cancer have steadily improved from 10% to current rates that approach 80% ( 60 ). Unfortunately, many long-term survivors of pediatric cancer develop chemotherapy-related health effects; 25% are afflicted with a severe or life-threatening medical condition, with cardiovascular disease being a primary risk ( 96 ). Childhood cancer survivors have markedly elevated incidences of stroke, congestive heart failure (CHF), coronary artery disease, and valvular disease ( 96 ). Their cardi

APA, Harvard, Vancouver, ISO, and other styles

19

van Nimwegen, Frederika A., Michael Schaapveld, David J. Cutter, et al. "Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma." Journal of Clinical Oncology 34, no. 3 (2016): 235–43. http://dx.doi.org/10.1200/jco.2015.63.4444.

Full text

Abstract:

Purpose Cardiovascular diseases are increasingly recognized as late effects of Hodgkin lymphoma (HL) treatment. The purpose of this study was to identify the risk factors for coronary heart disease (CHD) and to quantify the effects of radiation dose to the heart, chemotherapy, and other cardiovascular risk factors. Patients and Methods We conducted a nested case-control study in a cohort of 2,617 5-year HL survivors, treated between 1965 and 1995. Cases were patients diagnosed with CHD as their first cardiovascular event after HL. Detailed treatment information was collected from medical recor

APA, Harvard, Vancouver, ISO, and other styles

20

Drapkina, O. M., A. A. Zeynapur, A. S. Klevina, and O. B. Vasileva. "Thoracalgia in a Patient with Determined Coronary Heart Disease. Is there Always a Relapse of Angina Pectoris?" Rational Pharmacotherapy in Cardiology 16, no. 1 (2020): 46–50. http://dx.doi.org/10.20996/1819-6446-2020-02-05.

Full text

Abstract:

This article presents a clinical case of a 62-year-old man with a long history of coronary heart disease and smoking, whose main complaint upon admission to the hospital was voice hoarseness and atypical pain syndrome in the chest. During a preliminary medical examination, attention was paid to the clinical picture, atypical for a coronary heart disease – voice hoarseness was identified as a manifestation of the recurrent nerve compression, or cardio-vocal syndrome. Given the lack of connection between the chest pain and physical exertion, a high index of a smoking person as well as signs of t

APA, Harvard, Vancouver, ISO, and other styles

21

Pinder, Mary C., Zhigang Duan, James S. Goodwin, Gabriel N. Hortobagyi, and Sharon H. Giordano. "Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer." Journal of Clinical Oncology 25, no. 25 (2007): 3808–15. http://dx.doi.org/10.1200/jco.2006.10.4976.

Full text

Abstract:

Purpose Limited data are available on long-term cardiac safety of adjuvant anthracycline chemotherapy in breast cancer patients over age 65 years. We evaluated rates and predictors of congestive heart failure (CHF) in this population. Patients and Methods We used the Surveillance, Epidemiology, and End Results Medicare database and included women with no history of CHF who were age 66 to 80 years and diagnosed with stage I to III breast cancer from 1992 to 2002. Cumulative rates of CHF were estimated, and multivariable Cox regression analysis was used to determine factors associated with the d

APA, Harvard, Vancouver, ISO, and other styles

22

Baker, Laurence H., Venkatesh Locharla Murthy, Richard Lawrence Weinberg, Jose Jalife, and Todd Herron. "Evaluation of cardiovascular health in sarcoma survivors." Journal of Clinical Oncology 35, no. 15_suppl (2017): e21579-e21579. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e21579.

Full text

Abstract:

e21579 Background: Heart disease is the most common and serious chronic illness observed in sarcoma survivors treated with doxorubicin. Now the commonest heart disease in theses survivors is coronary artery disease (CAD). We established a Sarcoma Survivorship Program to include patients at high risk of chronic illness including exposure to doxorubicin who are at least 2 years free of disease post treatment. Methods: Every 6 months patients electronically complete NIH’s PROMIS (Patient-Reported Outcomes Measurement Information System) questionnaires (on Anxiety, Depression, Mobility, Pain Inter

APA, Harvard, Vancouver, ISO, and other styles

23

Kritz, H., C. Zielinski, and H. Sinzinger. "Low cholesterol and cancer." Journal of Clinical Oncology 14, no. 11 (1996): 3043–48. http://dx.doi.org/10.1200/jco.1996.14.11.3043.

Full text

Abstract:

PURPOSE The relation between plasma cholesterol (CH) concentration and mortality is complex. The plasma CH concentration correlates positively with mortality from coronary heart disease, but some studies have shown a negative relation with death from cancer. If these two relations reflect causal mechanisms that are reversible by changing the plasma CH concentration, the benefits of lipid reduction for heart disease might be offset by an increased mortality from cancer. Different aspects between lipid metabolism and cancer, as well as new insights into this interesting field, are discussed. MET

APA, Harvard, Vancouver, ISO, and other styles

24

Paulenka, Yuliya, Maritza Cotto, Christine Rickette, and Krystal Hunter. "Latent atherosclerosis as a risk factor in chemotherapy-induced cardiomyopathy." Journal of Clinical Oncology 39, no. 15_suppl (2021): e12525-e12525. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e12525.

Full text

Abstract:

e12525 Background: Anthracyclines and monoclonal antibodies targeting HER2/neu receptors are widely used antineoplastic agents in breast cancer treatment. Both therapies have been known to cause cardiovascular adverse effects, notably chemotherapy-induced congestive heart failure, especially if used in combination. Multiple factors have been postulated to increase the risk of doxorubicin and trastuzumab-associated cardiotoxicity, including a pre-existing coronary artery disease, but the role of latent atherosclerosis has not been widely studied. Methods: We retrospectively reviewed health reco

APA, Harvard, Vancouver, ISO, and other styles

25

Jain, Angita, Nadine Norton, Katelyn A. Bruno, Leslie T. Cooper, Paldeep S. Atwal, and DeLisa Fairweather. "Sex Differences, Genetic and Environmental Influences on Dilated Cardiomyopathy." Journal of Clinical Medicine 10, no. 11 (2021): 2289. http://dx.doi.org/10.3390/jcm10112289.

Full text

Abstract:

Dilated cardiomyopathy (DCM) is characterized by dilatation of the left ventricle and impaired systolic function and is the second most common cause of heart failure after coronary heart disease. The etiology of DCM is diverse including genetic pathogenic variants, infection, inflammation, autoimmune diseases, exposure to chemicals/toxins as well as endocrine and neuromuscular causes. DCM is inherited in 20–50% of cases where more than 30 genes have been implicated in the development of DCM with pathogenic variants in TTN (Titin) most frequently associated with disease. Even though male sex is

APA, Harvard, Vancouver, ISO, and other styles

26

Chitu, Monica, Theodora Benedek, S. Condrea, C. Blendea, and I. Benedek. "An unusual case of cardiac syncope and acute coronary syndrome – a case report." Acta Medica Marisiensis 60, no. 6 (2014): 285–87. http://dx.doi.org/10.1515/amma-2015-0011.

Full text

Abstract:

Abstract Introduction: We aimed to present a case of acute coronary syndrome with unexpected etiology complicated by syncope and arrhythmias, confirmed by imagistic examinations as cardiac parasitosis. Cardiac parasitic diseases are rare diseases, whose diagnosis and therapy should be adapted to each case. Imaging techniques allow precise diagnosis of cardiac echinococcosis, providing essential structural details on the damage degree of heart structures, allowing optimization of complex treatment in these cases. Case presentation: A 67-year old, obese and diabetic woman presented with cardiac

APA, Harvard, Vancouver, ISO, and other styles

27

Watson, G. J., M. R. Kugel, H. Shih, C. Tak Piech, and R. S. McKenzie. "Cardiac cormorbidities in women with metastatic breast cancer treated with doxorubicin-based and non-doxorubicin-based chemotherapy." Journal of Clinical Oncology 27, no. 15_suppl (2009): 1052. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.1052.

Full text

Abstract:

1052 Background: Observational data are sparse regarding cardiac comorbidities in patients with metastatic breast cancer (MBC) newly initiated on chemotherapy. As some MBC treatments are associated with cardiac toxicity, such information would be useful in guiding treatment decisions. The objective of this analysis was to understand the frequency of cardiac comorbidities in MBC patients prior to chemotherapy initiation based on the Medicare 5% standard analytical file (SAF). Methods: The Medicare 5% SAF was used to investigate claims for women with breast neoplasm and > 1 distant metastatic

APA, Harvard, Vancouver, ISO, and other styles

28

Steuter, John Allen, Philip Bierman, R. Gregory Bociek, and Martin Bast. "Utility Of Pre-Chemotherapy Echocardiograms." Blood 122, no. 21 (2013): 2950. http://dx.doi.org/10.1182/blood.v122.21.2950.2950.

Full text

Abstract:

Abstract Anthracycline-based chemotherapy is widely used in a variety of regimens for Hodgkin’s Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL). Unfortunately this agent is associated with cardiotoxicity, especially in larger cumulative doses. Doxorubicin cardiotoxicity is characterized by a dose-dependent decline in mitochondrial oxidative phosphorylation. Reactive oxygen species, generated by the interaction of doxorubicin with iron, can then damage the myocytes causing myofibrillar loss, cytoplasmic vacuolization, and apoptosis. Current NCCN guidelines for HL and NHL state that left ventricl

APA, Harvard, Vancouver, ISO, and other styles

29

Armenian, Saro H., Gregory T. Armstrong, Gregory Aune, et al. "Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention." Journal of Clinical Oncology 36, no. 21 (2018): 2135–44. http://dx.doi.org/10.1200/jco.2017.76.3920.

Full text

Abstract:

Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largely attributable to treatment exposures at a young age, most notably anthracycline chemotherapy and chest-directed radiation therapy, and compounded by traditional cardiovascular risk factors accrued during decades after treatment exposure. Preclinical studies are limited; thus, it is a high priority

APA, Harvard, Vancouver, ISO, and other styles

30

Hancock, S. L., S. S. Donaldson, and R. T. Hoppe. "Cardiac disease following treatment of Hodgkin's disease in children and adolescents." Journal of Clinical Oncology 11, no. 7 (1993): 1208–15. http://dx.doi.org/10.1200/jco.1993.11.7.1208.

Full text

Abstract:

PURPOSE Cardiac disease is second only to neoplastic disease as a cause of death after treatment for Hodgkin's disease. This study evaluates the risks of cardiac disease following treatment of Hodgkin's disease during childhood and adolescence. PATIENTS AND METHODS We reviewed records of 635 patients treated for Hodgkin's disease before 21 years of age at Stanford University between 1961 and 1991. Mean age was 15.4 years; mean follow-up duration was 10.3 years, representing 6,564 person-years of observation. Relative risks (RRs) of death from cardiac diseases were calculated by comparison with

APA, Harvard, Vancouver, ISO, and other styles

31

Loria, Valentina, Christian Colizzi, Marcello Vaccarella, Francesco Franceschi, and Nadia Aspromonte. "Left Ventricular Noncompaction: Cause or Consequence of Myocardial Disease? A Case Report and Literature Review." Cardiology 143, no. 3-4 (2019): 100–104. http://dx.doi.org/10.1159/000500904.

Full text

Abstract:

A 57-year-old woman presented to the Emergency Department with symptoms of worsening heart failure (HF). She had a past medical history of breast cancer treated with surgery and chemotherapy with anthracyclines and no family history of cardiomyopathy (CMP). In the last year, she received a diagnosis of HF with normal coronary arteries, during hospitalization for acute onset of dyspnea and was treated with medical therapy. After several months, few days before admission to our hospital, an echocardiography (ECHO) showed features of left ventricular noncompaction (LVNC), not described in previou

APA, Harvard, Vancouver, ISO, and other styles

32

Zaborowska-Szmit, Magdalena, Maciej Krzakowski, Dariusz M. Kowalski, and Sebastian Szmit. "Cardiovascular Complications of Systemic Therapy in Non-Small-Cell Lung Cancer." Journal of Clinical Medicine 9, no. 5 (2020): 1268. http://dx.doi.org/10.3390/jcm9051268.

Full text

Abstract:

Cardiovascular diseases may determine therapy outcomes of non-small-cell lung cancer (NSCLC). The evidence for how iatrogenic cardiovascular complications contribute to ceasing anticancer treatment, decreasing the quality of life or even premature death, is unclear. Older patients and smokers are at risk of atherosclerosis and arterial thromboembolic events (TE), such as myocardial infarction or stroke. Venous TE can be observed in up to 15% of NSCLC patients, but the risk increases three to five times in ALK (anaplastic lymphoma kinase)-rearranged NSCLC. ALK inhibitors are associated with ele

APA, Harvard, Vancouver, ISO, and other styles

33

Charkviani, Mariam, Natia Murvelashvili, Francisco Barrera, Alisha Sharma, Randa Sharag Eldin, and Nur Un Nisa Nabil. "Rare Presentation of Cardiotoxicity Related to 5-Fluorouracil." Case Reports in Oncological Medicine 2020 (July 21, 2020): 1–4. http://dx.doi.org/10.1155/2020/4151474.

Full text

Abstract:

5-Fluorouracil (5-FU) is a chemotherapeutic agent frequently used for the treatment of solid tumors. In a few cases, 5-FU can be associated with coronary vasospasm, cardiac ischemia, or life-threatening arrhythmias. Recognition of 5-FU cardiotoxicity is clinically important as after the rapid sensation of therapy, cardiotoxicity can be completely reversible, and on the other hand, readministration may lead to serious damage of the heart and even death. A 70-year-old male came to the emergency department (ED) with chest pain which started while receiving an infusion of 5-FU. The patient did not

APA, Harvard, Vancouver, ISO, and other styles

34

Hinduja, Archana, Kaustubh Limaye, Rahul Ravilla, Appalanaidu Sasapu, Xenofon Papanikolaou, and Sarah Waheed. "Spectrum of Cerebrovascular Disease in Multiple Myeloma Patients Undergoing Chemotherapy." Blood 126, no. 23 (2015): 5498. http://dx.doi.org/10.1182/blood.v126.23.5498.5498.

Full text

Abstract:

Abstract Introduction: The objective of study was to determine the risk factors, stroke mechanisms and outcome following a stroke in Multiple myeloma (MM) patients. Materials and Methods: We conducted a matched cohort study from a prospective database of MM patients enrolled in TT2, TT3A, TT3B protocols who developed a vascular event (transient ischemic attack, ischemic stroke and intracerebral hemorrhage) from 1998 to 2014 with age, sex and treatment matched controls. Comparison of baseline demographics, risk factors, myeloma characteristics, laboratory values and mortality between both group

APA, Harvard, Vancouver, ISO, and other styles

35

Huang, Sheng-Miauh, Li-Yin Chien, Cheng-Jeng Tai, Ling-Ming Tseng, Ping-Ho Chen, and Chen-Jei Tai. "Increases in Xu Zheng and Yu Zheng among Patients with Breast Cancer Receiving Different Anticancer Drug Therapies." Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–8. http://dx.doi.org/10.1155/2013/392024.

Full text

Abstract:

Aim. The objectives of this study were to compare yang-xu, yin-xu, and yu among patients with breast cancer right before, one month after, and three months after receiving target, chemo, or combined therapy.Method. After recruiting 126 patients from 4 hospitals in northern Taiwan, a longitudinal study was carried out with 61 patients receiving chemotherapy, 30 receiving target therapy, and 35 receiving combined therapy. Yang-xu, yin-xu, and yu were assessed using the Traditional Chinese Medical Constitutional Scale (TCMCS), with higher scores indicating more xu and yu.Results. There were signi

APA, Harvard, Vancouver, ISO, and other styles

36

Chavez-Mac Gregor, Mariana, Ning Zhang, Jiangong Niu, et al. "Trastuzumab-related cardiotoxicity among older breast cancer patients." Journal of Clinical Oncology 30, no. 27_suppl (2012): 135. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.135.

Full text

Abstract:

135 Background: The use of trastuzumab in the adjuvant setting is associated with reduction in mortality and recurrence. Trastuzumab is extremely well tolerated, but its use is associated with congestive heart failure (CHF). The incidence of this complication in the general population remains largely unknown, especially in older patients. In this study we evaluated the rates and risk factors associated with trastuzumab-related CHF in a large cohort of older breast cancer patients. Methods: Breast cancer patients > 66 years with full Medicare coverage, diagnosed with stage I-III breast cance

APA, Harvard, Vancouver, ISO, and other styles

37

Chavez-Mac Gregor, Mariana, Ning Zhang, Thomas A. Buchholz, et al. "Trastuzumab-related cardiotoxicity among older breast cancer patients." Journal of Clinical Oncology 30, no. 15_suppl (2012): 600. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.600.

Full text

Abstract:

600 Background: The use of trastuzumab in the adjuvant setting is associated with reduction in mortality and recurrence. Although trastuzumab is extremely well tolerated, its use is associated with congestive heart failure (CHF). The incidence of this complication in the general population remains largely unknown, especially in older patients. In this study we evaluated the rates and risk factors associated with trastuzumab-related CHF in a large cohort of older breast cancer patients. Methods: Breast cancer patients ≥ 66 years with full Medicare coverage, diagnosed with stage I-III breast can

APA, Harvard, Vancouver, ISO, and other styles

38

Peippo, Maija Helena, Samu Kurki, Riitta Lassila, and Olli Mikael Carpén. "Real-world features associated with cancer-related venous thromboembolic events." ESMO Open 3, no. 5 (2018): e000363. http://dx.doi.org/10.1136/esmoopen-2018-000363.

Full text

Abstract:

BackgroundThe incidence of venous thromboembolism (VTE) is 1–2/1000 individuals. Patients with cancer, especially during chemotherapy, are at enhanced risk, but real-world data on factors associated with VTE events are still scarce.AimThe aim of this retrospective study was to survey the incidence of VTE based on a large hospital database, and to identify comorbidities and features associated with VTE events. We focused on cancer-related VTE events and on factors indicating increased VTE risk during chemotherapy.MethodsThe cohort included patients treated at Turku University Hospital during ye

APA, Harvard, Vancouver, ISO, and other styles

39

Ivovic, Miomira, Biljana Radojkovic, Zorana Penezic, et al. "Agranulocytosis and acute coronary syndrom in apathetic hyperthyreoidism." Srpski arhiv za celokupno lekarstvo 131, no. 5-6 (2003): 249–53. http://dx.doi.org/10.2298/sarh0306249i.

Full text

Abstract:

INTRODUCTION Tissue expose to excessive levels of circulating thyroid hormones results in thyrotoxicosis. In most cases, thyrotoxicosis is due to hyper-activity of the thyroid gland. Cardiovascular and myopathic manifestations are predominant clinical features in most hyperthyroid patients, aged 60 years and older. Some of patients have apathetic hyperthyreoidism which presents with weight loss, small goiter, severe depression and without clinical features of increased sympathetic activity [3, 6]. About 50% of patients with cardiovascular manifestations have no evidence of underlying heart dis

APA, Harvard, Vancouver, ISO, and other styles

40

Peters, Christopher A., Andrew Kaleda, Anthony Manfredo, Elizabeth Tapen, and Lawrence Koutcher. "Cardiac dose evaluation in patients undergoing breast radiotherapy in the modern era." Journal of Clinical Oncology 32, no. 26_suppl (2014): 78. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.78.

Full text

Abstract:

78 Background: Breast radiotherapy (RT) after conservative surgery improves overall survival and minimizes locoregional recurrence. The therapeutic ratio of adjuvant RT continues to improve with time. Cardiac toxicity from breast cancer treatment remains a concern, and can result from chemotherapy, biologic therapy, or RT in a dose-dependent fashion. Dose to avoidance structures can be minimized as technological improvements in radiotherapy evolve. We sought to investigate heart and coronary artery dose using modern RT techniques. Methods: We reviewed 164 consecutive non-metastatic breast canc

APA, Harvard, Vancouver, ISO, and other styles

41

Dreyling, Martin, Sebastian Fetscher, P. Kornek, et al. "Treatment of Indolent Non-Hodgkin’s Lymphoma in Germany - Results of a Representative Population-Based Survey." Blood 110, no. 11 (2007): 1353. http://dx.doi.org/10.1182/blood.v110.11.1353.1353.

Full text

Abstract:

Abstract In advanced stage indolent lymphoma, therapeutic approaches may vary from watch and wait, antibody monotherapy, conventional chemotherapy or dose-intensified consolidation up to allogeneic strategies. In this nation-wide survey, representative hematological/oncological centers monitored current treatment strategies under routine conditions. 495 centers involved in the treatment of indolent lymphoma including university hospitals (UH), community hospitals (CH), and office-based hematologists (OBH) were contacted. 13% of identified centers provided information on 741 patients correspond

APA, Harvard, Vancouver, ISO, and other styles

42

Blann, Andrew D., and Simon Dunmore. "Arterial and Venous Thrombosis in Cancer Patients." Cardiology Research and Practice 2011 (2011): 1–11. http://dx.doi.org/10.4061/2011/394740.

Full text

Abstract:

The most frequent ultimate cause of death is myocardial arrest. In many cases this is due to myocardial hypoxia, generally arising from failure of the coronary macro- and microcirculation to deliver enough oxygenated red cells to the cardiomyocytes. The principle reason for this is occlusive thrombosis, either by isolated circulating thrombi, or by rupture of upstream plaque. However, an additionally serious pathology causing potentially fatal stress to the heart is extra-cardiac disease, such as pulmonary hypertension. A primary cause of the latter is pulmonary embolus, considered to be a ven

APA, Harvard, Vancouver, ISO, and other styles

43

Cramer, Paula, Valentin Goede, Petra Jenke, Raymonde Busch, Michael Hallek, and Barbara Eichhorst. "Impact of Different Chemotherapy Regimen in Comorbid Patients with Advanced Chronic Lymphocytic Leukemia: Metaanalysis of Two Phase-III-Trials of the German CLL Study Group." Blood 108, no. 11 (2006): 2840. http://dx.doi.org/10.1182/blood.v108.11.2840.2840.

Full text

Abstract:

Abstract Introduction: Since chronic lymphocytic leukemia (CLL) is a disease of elderly patients (pts) comorbidity is a frequent feature which has already been shown to be associated with survival-shortening in lymphoma patients. It has been hypothesized that intensity of chemotherapy may interfere with treatment outcome, but the precise mechanisms underlying the impact of comorbidity are still not understood. Consequently, comorbitity currently keeps away oncologists from administering intense combined (immuno−)chemotherapy to pts with CLL and concomitant diseases. Patients & methods: 554

APA, Harvard, Vancouver, ISO, and other styles

44

Kattih, Badder, Amir Shirvani, Piroska Klement, et al. "IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML." Blood 136, Supplement 1 (2020): 32–33. http://dx.doi.org/10.1182/blood-2020-143026.

Full text

Abstract:

Introduction: Clonal hematopoiesis initiated by acquired somatic mutations in hematopoietic cells has been identified as an independent driver of increased all-cause mortality, risk of coronary artery disease and heart failure. Oncogenic mutations in isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) lead to conversion of αKG to R-2-hydroxyglutarate (R-2HG), which is a competitive inhibitor of TET2 and a known oncometabolite. Oncometabolite R-2HG (produced by IDH mutant cells) has been implicated in pathological cardiac remodeling and dysfunction in preclinical studies. Whether IDH mutant leuke

APA, Harvard, Vancouver, ISO, and other styles

45

Chen, John H., Daniel J. Lenihan, Sharon E. Phillips, et al. "Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma." Blood 126, no. 23 (2015): 5363. http://dx.doi.org/10.1182/blood.v126.23.5363.5363.

Full text

Abstract:

Abstract Introduction Proteasome inhibitors (PI) bortezomib (B) and carfilzomib (C) are cornerstone therapies for multiple myeloma (MM). An increased incidence of PI-induced cardiac adverse events (CAEs) has been reported in patients receiving C. However, risk factors for cardiac toxicity in this population remain unclear. Our objective is to evaluate the incidence of CAEs associated with C compared with B and identify risk factors for developing events. Patients and Method This was a retrospective analysis of 96 consecutive patients treated for MM at Vanderbilt University from 2011 to 2014 wh

APA, Harvard, Vancouver, ISO, and other styles

46

Hu, Min, Tianyu Li, Zixiang Bo, and Feixiang Xiang. "The protective role of carnosic acid in ischemic/reperfusion injury through regulation of autophagy under T2DM." Experimental Biology and Medicine 244, no. 7 (2019): 602–11. http://dx.doi.org/10.1177/1535370219840987.

Full text

Abstract:

Ischemic heart disease (IHD) is the most common cardiovascular disease and is the main cause of death and disability worldwide. Myocardial ischemia/reperfusion (MI/R) injury has been linked to IHD-induced cardiomyocytes apoptosis and tissue damage. Recently, it has been reported that carnosic acid (CA) may function as a potent antioxidant in liver ischemia/reperfusion (I/R). However, whether it regulates I/R in the heart remains unclear. Here, we elucidated the emerging role of CA in MI/R under diabetic myocardial conditions. Diabetes mellitus (DM) was induced in mice by consumption of a high-

APA, Harvard, Vancouver, ISO, and other styles

47

de Haas, E. C., N. Zwart, C. Meijer, et al. "Association of plasminogen-activator inhibitor 1 (PAI-1) 4G/5G gene polymorphism with survival and chemotherapy-related vascular toxicity in non-seminomatous testicular cancer (TC)." Journal of Clinical Oncology 27, no. 15_suppl (2009): 5083. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.5083.

Full text

Abstract:

5083 Background: High PAI-1 expression by tumor has been associated with poor prognosis in different cancer types, while high systemic PAI-1 levels may increase the risk of vascular thrombosis. We investigated whether the 4G/5G del/ins polymorphism in the PAI-1 promoter (rs1799889; 4G might lead to higher transcription), is associated with differences in survival and prevalence of cardiovascular events in TC. Methods: Data were collected on survival and cardiovascular events (venous thromboembolism [VTE] and coronary heart disease [CHD]) of TC patients treated with standard platinum based chem

APA, Harvard, Vancouver, ISO, and other styles

48

Glimelius, Ingrid, Karin Ekstroem Smedby, Mats Jerkeman, Sandra Eloranta, and Caroline Weibull. "Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma Patients, a Swedish Lymphoma Registry Study." Blood 132, Supplement 1 (2018): 2891. http://dx.doi.org/10.1182/blood-2018-99-111471.

Full text

Abstract:

Abstract Purpose The prognosis for patients with mantle cell lymphoma (MCL) is rather dismal where particularly elderly patients, often with comorbidities, have difficulties tolerating the intensive treatments needed for long-term remission. Our aim was to describe the frequency and spectrum of comorbidities among patients with MCL in a population-based setting, and assess the impact of comorbidities on treatment choice, lymphoma-specific and overall survival as well as causes of death in MCL patients by age and sex. Methods In the nationwide Swedish Lymphoma Register, we identified 1,385 MCL

APA, Harvard, Vancouver, ISO, and other styles

49

Gaddh, Manila, Bernice Fokum, Hamid Bouiri, Augustin Haidau, and Margaret Telfer. "Prologed Use of Pegylated Liposomal Doxorubicin In An HIV-Infected Population with Kaposi's Sarcoma at An Inner-City Safety Net Hospital." Blood 116, no. 21 (2010): 4873. http://dx.doi.org/10.1182/blood.v116.21.4873.4873.

Full text

Abstract:

Abstract Abstract 4873 Introduction: Kaposi's sarcoma (KS) is a low-grade HHV-8 associated vascular tumor that is particularly prevalent in patients infected with HIV. The mainstay of treatment is HAART, which has decreased the aggressiveness, and possibly the prevalence of this disease. Cytotoxic chemotherapy is generally added for moderate to severe symptomatic disease, with Pegylated Liposomal Doxorubicin (Doxil) being the treatment of choice. Studies have shown that unlike regular anthracyclines, Doxil can be safely administered over long periods at low doses without inducing cardio toxici

APA, Harvard, Vancouver, ISO, and other styles

50

Chavez-MacGregor, Mariana, Ning Zhang, Thomas A. Buchholz, et al. "Trastuzumab-Related Cardiotoxicity Among Older Patients With Breast Cancer." Journal of Clinical Oncology 31, no. 33 (2013): 4222–28. http://dx.doi.org/10.1200/jco.2013.48.7884.

Full text

Abstract:

Purpose The use of trastuzumab in the adjuvant setting improves outcomes but is associated with cardiotoxicity manifested as congestive heart failure (CHF). The rates and risk factors associated with trastuzumab-related CHF among older patients are unknown. Patients and Methods Breast cancer patients at least 66 years old with full Medicare coverage, diagnosed with stage I-III breast cancer between 2005 and 2009, and treated with chemotherapy were identified in the SEER-Medicare and in the Texas Cancer Registry–Medicare databases. The rates and risk factors associated with CHF were evaluated.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!